- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07355829
DemTool - Supporting Life With Dementia (DemTool)
January 13, 2026 updated by: Danish Dementia Research Centre
This study will investigate the effects of a Danish psychosocial intervention, specifically the DemTool - supporting life with dementia, on quality of life and caregiver strain in family caregivers of people with dementia.
Study Overview
Status
Completed
Conditions
Detailed Description
'DemTool - supporting life with dementia' was developed in Denmark by the Danish Dementia Research Centre with a focus on improving the quality of life of people with dementia and their family caregivers.
DemTool was developed to assist professional caregivers in Danish municipalities.
It is intended for use by professionals responsible for counseling and educating patients and their family caregivers in primary care settings.
This study will examine the impact of DemTool on the quality of life and caregiver strain among family caregivers of individuals with dementia using self-reported data from questionnaires.
Family caregivers who participated in the intervention were invited to complete a questionnaire before their inclusion in the study, which served as a baseline measure.
They then filled out a follow-up questionnaire approximately one month after receiving their last intervention.
Meanwhile, the treatment-as-usual group also completed a questionnaire before study inclusion and received a follow-up questionnaire two months after the baseline measure.
Study Type
Interventional
Enrollment (Actual)
272
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Danish Dementia Research Centre, Rigshospitalet, University of Copenhagen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥18 years at enrollment.
- Providing care for a family member with dementia.
- Speaking and understanding Danish.
Exclusion Criteria:
- Unable to give informed consent for the trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
The trial included 15 municipalities in the intervention group.
Family caregivers in the intervention group received one or two of the tailored interventions based on their level of burden and specific needs, as assessed by the local primary care dementia coordinator in the municipality.
The interventions included: 1) a support group focused on addressing caregiver burden, providing both professional and peer support; 2) a group course consisting of six sessions aimed at helping caregivers cope with everyday challenges; and 3) a group course over five sessions that offered information on dementia, transitioning to a nursing home, person-centered care, and effective communication strategies.
|
This intervention aimed to promote coping and reduce caregiver burden through professional and peer support.
It was delivered over a varied number of sessions, as this depended on the number of recruited participants in the municipalities.
To support these sessions, booklets and fact sheets for family caregivers could be incorporated.
These materials would cover various topics, including the psychological challenges and reactions faced by family caregivers, guidance on effective communication with people with dementia, and a guide to practical and legal issues.
Further, there would be fact sheets addressing specific symptoms, such as memory loss, communication difficulties, depression, apathy, behavioral changes, and reduced awareness of symptoms.
The use of these booklets and fact sheets in the intervention would be determined by the municipalities, allowing for adaptation to fit local contexts.
Dementia coordinators within the community setting would implement this intervention.
This intervention aimed to provide information on, e.g., dementia diseases, everyday life with dementia, being a family caregiver, and planning the future.
It was delivered over six sessions.
To support the sessions, booklets and fact sheets for family caregivers were incorporated.
Materials covered various topics, including, e.g., the psychological challenges and reactions faced by family caregivers, and information on accessing support and services.
Additionally, fact sheets addressed specific symptoms, such as memory loss, communication difficulties, apathy, and behavioral changes.
To support municipalities in implementing this intervention, the Danish Dementia Research Centre provided PowerPoint presentations and a suggested order for the topics covered in each session.
However, municipalities have the flexibility to adapt the use of the PowerPoints and the sequence of the sessions to suit their local contexts.
This was done by dementia coordinators within the community setting.
This intervention aimed to provide information on dementia diseases, moving into a care home, person centered care, and communication.
It was delivered over five sessions.
To support the sessions, booklets and fact sheets for family caregivers were incorporated.
Materials covered various topics, including, e.g., psychological challenges and reactions faced by family caregivers, and guidance on effective communication with people with dementia.
Additionally, fact sheets addressed specific symptoms, such as memory loss, communication difficulties, behavioral changes, and reduced awareness of symptoms.
To support municipalities in implementing this, the Danish Dementia Research Centre provided PowerPoint presentations and a suggested order for the topics covered in each session.
However, municipalities have the flexibility to adapt the use of PowerPoints and the sequence of sessions to suit their local contexts.
This was carried out by dementia coordinators within the community setting.
|
|
No Intervention: Treatment-as-usual
The trial included 15 municipalities in the treatment-as-usual group.
Family caregivers in the treatment-as-usual group had access to local health and social services in their municipality, including support and information from primary care dementia coordinators, support groups, hotlines provided by patient associations, and respite care for the person with dementia in a home or daycare setting.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in Neuropsychiatric Inventory - Distress (NPI-D)
Time Frame: Outcome were measured at baseline (study inclusion) and follow-up (1 month after the last received intervention and 2 months from baseline in the treatment-as-usual group).
|
Used to measure the emotional and psychological burden experienced by caregivers of patients with dementia.
|
Outcome were measured at baseline (study inclusion) and follow-up (1 month after the last received intervention and 2 months from baseline in the treatment-as-usual group).
|
|
Change from baseline in European Quality of Life-Visual Analogue Scale (EQ VAS).
Time Frame: Outcome were measured at baseline (study inclusion) and follow-up (1 month after the last received intervention and 2 months from baseline in the treatment-as-usual group).
|
Used to measure a person's self-assessed general health on a given day.
It's a vertical line scale from 0 (worst imaginable health) to 100 (best imaginable health), where respondents mark their current health state.
|
Outcome were measured at baseline (study inclusion) and follow-up (1 month after the last received intervention and 2 months from baseline in the treatment-as-usual group).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in the 5-level EQ-5D version (EQ-5D-5L).
Time Frame: Outcome were measured at baseline (study inclusion) and follow-up (1 month after the last received intervention and 2 months from baseline in the treatment-as-usual group).
|
Used to measure quality of life in five dimensions, on a 5-point likert scale.
Completing it generates a one-digit number for each dimension, which can be converted into a utility score.
The closer the utility value is to 1, the better the health state.
The EQ-5D-5L utility ranges from -0.757 to 1.
|
Outcome were measured at baseline (study inclusion) and follow-up (1 month after the last received intervention and 2 months from baseline in the treatment-as-usual group).
|
|
Change from baseline in World Health Organization Wellbeing Index (WHO-5).
Time Frame: Outcome were measured at baseline (study inclusion) and follow-up (1 month after the last received intervention and 2 months from baseline in the treatment-as-usual group).
|
Assesses subjective psychological well-being over the past two weeks.
Five questions are rated on a 6-point Likert scale.
A higher score indicates better wellbeing.
|
Outcome were measured at baseline (study inclusion) and follow-up (1 month after the last received intervention and 2 months from baseline in the treatment-as-usual group).
|
|
Change from baseline in University of California, Los Angeles Three-Item Loneliness Scale (UCLA 3-item).
Time Frame: Outcome were measured at baseline (study inclusion) and follow-up (1 month after the last received intervention and 2 months from baseline in the treatment-as-usual group).
|
Used to assess feelings of loneliness or social isolation via three questions on relational and social connectedness, and self-perceived isolation, rated on a 3-point Likert scale.
Higher scores reflect greater loneliness.
|
Outcome were measured at baseline (study inclusion) and follow-up (1 month after the last received intervention and 2 months from baseline in the treatment-as-usual group).
|
|
Change from baseline in Carer Experience Scale (CES).
Time Frame: Outcome were measured at baseline (study inclusion) and follow-up (1 month after the last received intervention and 2 months from baseline in the treatment-as-usual group).
|
A measure of caregiving experience in everyday life operationalized in six questions on a 3-point Likert scale.
A total index score, calculated by adding preference weights, ranges from 0 to 100, where 0 indicates the poorest and 100 the best caregiving experience.
|
Outcome were measured at baseline (study inclusion) and follow-up (1 month after the last received intervention and 2 months from baseline in the treatment-as-usual group).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gunhild Waldemar, MD, D.M.Sc, Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark.
- Principal Investigator: T. Rune Nielsen, PhD, Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark.
- Principal Investigator: Ann Nielsen, MSPH, PhD, Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2021
Primary Completion (Actual)
January 24, 2024
Study Completion (Actual)
January 24, 2024
Study Registration Dates
First Submitted
December 10, 2025
First Submitted That Met QC Criteria
January 13, 2026
First Posted (Actual)
January 21, 2026
Study Record Updates
Last Update Posted (Actual)
January 21, 2026
Last Update Submitted That Met QC Criteria
January 13, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DemTool
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
While the study data are pseudonymized, participants did not consent to have their data shared with third parties beyond the study team.
The informed consent form clearly restricted data usage to analyses conducted within the project and the publication of aggregated results in scientific articles.
Sharing individual-level data would go beyond the original consent.
Therefore, the dataset cannot be made publicly available.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia (Diagnosis)
-
Nottingham University Hospitals NHS TrustRecruitingDementia (Diagnosis)United Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafNot yet recruitingMild Cognitive Impairment (MCI) | Loneliness | Dementia (Diagnosis)Spain
-
The Fourth Affiliated Hospital of Zhejiang University...RecruitingAlzheimer Disease | Biomarker in Early DiagnosisChina
-
Noah Tech, Corp.Not yet recruitingParkinson's Disease | Mild Cognitive Impairment (MCI) | Parkinson's Disease (PD) | Alzheimer's Disease Diagnosis | Alzheimer's Disease and Related Dementias | Alzheimer's Disease Dementia | Parkinson's Disease With Wearing-off Motor Fluctuations | Dementia (Diagnosis) | Dementia MCI (Mild Cognitive... and other conditionsUnited States
-
Helse Stavanger HFGöteborg University; Norwegian University of Science and TechnologyCompletedAlzheimer Disease | Mild Cognitive Impairment | Dementia of Alzheimer Type | Pathology | Biomarker in Early Diagnosis
-
University Hospital, Strasbourg, FranceRecruitingDementia With Lewy Bodies Diagnosis | Significant Cognitive Fluctuations in DLBFrance
-
Umraniye Education and Research HospitalCompleted
-
Anhui Provincial HospitalEnrolling by invitationAlzheimer's Disease DiagnosisChina
-
SuperSonic ImagineTerminated
-
Imperial College LondonNot yet recruitingMild Cognitive Impairment (MCI) | Alzheimer Disease | Biomarker in Early Diagnosis | Biomarkers / Blood
Clinical Trials on Life with dementia in the community - Support group for family caregivers
-
University of ValenciaCompletedPalliative CareSpain
-
Karolinska InstitutetStockholm City Council; Children's right in societyNot yet recruitingParent-Child Relations | ImmigrantSweden
-
Queen's University, BelfastFour Seasons Health CareUnknownNeurodegenerative Diseases | DementiaUnited Kingdom
-
Adina MaeirMonash UniversityRecruitingAttention Deficit Disorder With Hyperactivity (ADHD)Israel
-
University of Massachusetts, AmherstVanderbilt UniversityCompletedDepression | Stress, Psychological | Anxiety | Stress, PhysiologicalUnited States
-
Université de SherbrookeCanadian Institutes of Health Research (CIHR)Recruiting
-
University of Sao PauloUnknown
-
National Taiwan University HospitalCompletedHeart FailureTaiwan
-
University Hospital, ToulouseNot yet recruiting
-
The National Center on Addiction and Substance...Patient-Centered Outcomes Research InstituteCompletedADHD | Substance Use DisordersUnited States